<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Exploring High Growth Tech Stocks in the US Market September 2025 — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Exploring High Growth Tech Stocks in the US Market September 2025</h2>
    <div class="badge">2025-09-15T11:38:20+00:00</div>
    <ul>
      <li>The company&#x27;s commitment to shareholder value is evident through its aggressive share repurchase strategy, having bought back 600,000 shares for $10.7 million recently, completing nearly 10% of its announced buyback plan</li>
<li>The company&#x27;s strategic presence at key healthcare conferences signifies its active engagement in expanding industry influence and investor relations, while revised upward revenue guidance for 2025 between $625 million a</li>
<li>As of September 2025, the U.S.</li>
<li>Notably, Protagonist&#x27;s revenue is projected to grow at an impressive rate of 22% annually, outpacing the broader US market forecast of 9.6%.</li>
<li>Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $529.33 million.</li>
<li>This performance is underscored by an impressive annualized earnings growth rate of 36.9%, substantially outpacing the broader U.S market&#x27;s growth rate of 15.4%.</li>
<li>Operations: Protagonist Therapeutics focuses on developing peptide therapeutics, generating revenue primarily from its biotechnology segment, which reported $209.18 million.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Exploring High Growth Tech Stocks in the US Market September 2025\n• The company&#x27;s commitment to shareholder value is evident through its aggressive share repurchase strategy, having bought back 600,000 shares for $10.7 million recently, completing nearly 10% of its announced buyback plan\n• The company&#x27;s strategic presence at key healthcare conferences signifies its active engagement in expanding industry influence and investor relations, while revised upward revenue guidance for 2025 between $625 million a\n• As of September 2025, the U.S.\n• Notably, Protagonist&#x27;s revenue is projected to grow at an impressive rate of 22% annually, outpacing the broader US market forecast of 9.6%.\n• Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $529.33 million.\n• This performance is underscored by an impressive annualized earnings growth rate of 36.9%, substantially outpacing the broader U.S market&#x27;s growth rate of 15.4%.\n• Operations: Protagonist Therapeutics focuses on developing peptide therapeutics, generating revenue primarily from its biotechnology segment, which reported $209.18 million." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-113820579.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>